Skip to content
Monday 17 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE · FR
MorningWire

European business, markets and politics

FTSE 100
10,720.30
-0.28%
DAX
26,338.61
-0.38%
CAC 40
8,579.60
-0.66%
STOXX 50
6,530.45
-0.14%
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
More
GermanyFranceEU InstitutionsCompetitionPublic AffairsBankingTechnologyEnergy
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
  • DE
Wednesday 09 December 2020 10:15 am  |  Updated:  Wednesday 09 December 2020 10:46 am

Regulators prohibit Pfizer vaccine for people with ‘significant’ allergies after two NHS staff suffer reactions

By: Poppy Wood

Add as a preferred source on Google

Two NHS staff members who received the Pfizer/BioNTech vaccine on the first day of Britain’s mass vaccination programme yesterday suffered an allergic reaction, NHS England has confirmed.

UK regulators have now issued a warning that people who have a history of “significant” allergic reactions should not currently receive the Pfizer vaccine.

This applies to people with a history of anaphylaxis or who have been advised to carry a adrenaline autoinjector.

From now on, vaccination should only be carried out in places with resuscitation facilities, the Medicines and Healthcare products Regulatory Agency (MHRA) has said.

Both members of staff who suffered allergic reactions are understood to be recovering and all trusts involved with the vaccination programme have been informed.

Professor Stephen Powis, national medical director for the NHS in England, said: “As is common with new vaccines the MHRA have advised on a precautionary basis that people with a significant history of allergic reactions do not receive this vaccination after two people with a history of significant allergic reactions responded adversely yesterday.”

Dr June Raine, chief executive of the MHRA, told the Commons Science and Technology Committee this morning: “The role [of the MHRA’s assessment] is before, during, and after, and there is a true end to end, looking from the scientific laboratory bench through to the patient who yesterday, first received the vaccine. 

Read more

ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

“And as an illustration to this, I may share with the committee that even last evening we were looking at two case reports of allergic reactions. We know from the very extensive clinical trials that this wasn’t a feature. But if we need to strengthen our advice…. we get that advice to the field immediately.”

Raine added that “real-time vigilance” would continue even now the vaccine has been deployed.

It comes after 90-year-old Margaret Keenan yesterday became the first person in the world to receive a coronavirus vaccine outside of a trial, marking the start of Britain’s largest vaccination programme in history.

Around 800,000 doses are expected to be available in the UK by the end of the week, with care home residents and carers, the over-80s and some health service workers at the front of the queue.

In total, Britain has ordered 40m doses of the Pfizer/BioNTech vaccine — enough to vaccinate 20m people in a country of 67m.

Health officials will turn to other vaccines on the horizon to complete the UK’s vaccination programme, including the Astrazeneca/University of Oxford vaccine, of which the government has ordered 100m doses, and the Moderna vaccine, which the UK is set to receive 7m doses of.

Read more

NHS data counters claims that £330m Palantir deal has led to ‘no improvement’

Brit are seeking financial support from the ‘Bank of Mum and Dad’ to afford private healthcare.

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business

Related Topics

  • Coronavirus
  • Vaccine

Trending Articles

  • As it happened: FTSE 100 drops as oil prices rise after Trump makes Hormuz threat

  • US bond market jitters spark UK economy recession warning

  • Is the Zeekr 9X Super Hybrid the new luxury SUV to beat?

  • Grandparents fund university degrees to avoid inheritance tax net

  • Aldi boss wades into supermarket ‘price-gouging’ row

More from Morning Wire

  • ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

    Business Wire
  • NHS data counters claims that £330m Palantir deal has led to ‘no improvement’

    Tech
    Brit are seeking financial support from the ‘Bank of Mum and Dad’ to afford private healthcare.
  • Leeds NHS Innovation to Accelerate Global Adoption of AI-enabled Pathology for Cancer Diagnostics Through Epredia Partnership

    Business Wire
  • Ignore Palantir’s political opponents and look at the data: this technology helps patients

    Opinion
    NHS logo on a white surface with visible water droplets, blue and white branding
  • ‘Difficult decisions’ – Burnham looks at new tax on workers to fund social care overhaul

    Politics
    Andy Burnham, Mayor of Greater Manchester, discussing social care with an elderly man wearing a yarmulke.
  • From crown jewel to €180m courtroom battle: The investor revolt targeting Atos

    Markets
    Atos logo prominently displayed on a modern office building, highlighting its corporate presence and technological expertise.
  • Verdiva Bio Appoints Cardiometabolic Leader Steve Marso as Chief Medical Officer

    Business Wire
  • Screens aren’t the problem, it’s what’s on them that’s rotting our brains

    Opinion
    Unfortunately, without additional context from the article or details about what the image depicts, it is challenging to g...
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • EU Institutions
  • Europe

Business

  • Markets
  • Business
  • Economy
  • Regulation
  • Competition
  • Public Affairs

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook